Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.55 |
| ▸ | TDO2 | P48775 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 3/20 | 0.52 |
| ▸ | FEN1 | P39748 | 10/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504756 | 0.86 | ABL1 (0.68) | EIF2AK3TDO2ABL1FEN1ALOX5AP | |
| SCHEMBL23044427 | 0.84 | MAP4K4 (0.51) | EIF2AK3TDO2ABL1FEN1ALOX5AP | |
| SCHEMBL29690149 | 0.84 | MAP4K4 (0.51) | EIF2AK3TDO2ABL1FEN1ALOX5AP | |
| SCHEMBL4513696 | 0.82 | FEN1 (0.65) | TDO2FEN1ALOX5AP | |
| SCHEMBL4497183 | 0.81 | ABL1 (0.50) | EIF2AK3TDO2ABL1FEN1ALOX5AP | |
| SCHEMBL17805365 | 0.80 | NOS3 (0.47) | EIF2AK3TDO2ABL1FEN1NOS3 | |
| SCHEMBL3813235 | 0.80 | NOS3 (0.52) | EIF2AK3TDO2ABL1FEN1NOS3 | |
| SCHEMBL4503767 | 0.79 | TDO2 (0.54) | TDO2ABL1FEN1ALOX5APMAP4K4 | |
| SCHEMBL4489662 | 0.79 | FEN1 (0.51) | EIF2AK3TDO2ABL1FEN1ALOX5AP | |
| SCHEMBL15243549 | 0.78 | PDE3B (0.44) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211913-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | AMREIN KURT | 2009-06-11 | — | — | US | disclosed |
| US-7528159-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1789041-B1 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1789041-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | GPR119, CYP4B1, SLC5A1 | EIF2AK3 4273/4885TDO2 2985/4885ABL1 821/4885 |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | GPR119, CYP4B1, SLC5A1 | EIF2AK3 4273/4885TDO2 2985/4885ABL1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.